Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Human immunodeficiency virus type 1 (HIV-1) glycoprotein 41 (gp41) membrane-proximal external region (MPER) is a highly conserved, tryptophan-rich sequence located at the C-terminus of the gp41 ectodomain, adjacent to the viral transmembrane anchor (Sheng et al., 2014). It plays a pivotal role in the viral entry process by facilitating the fusion of the viral envelope with the host cell plasma membrane (Cardoso et al., 2005). Due to its critical function and low sequence variability across diverse HIV-1 clades, the MPER is a major target for broadly neutralizing antibodies (bNAbs) such as 4E10, 2F5, and 10E8 (Huang et al., 2012). These antibodies, particularly 4E10, recognize a linear epitope within the MPER and block the transition of gp41 into its fusogenic six-helix bundle conformation, thereby preventing infection (Sun et al., 2008). However, the MPER is partially occluded by the viral membrane and is only transiently exposed during the fusion process, making it a difficult target for vaccine-induced immunity (Haynes et al., 2005). Furthermore, some MPER-directed antibodies exhibit polyreactivity with host phospholipids, which poses potential safety concerns regarding autoimmunity and complicates the development of MPER-based therapeutics (Alam et al., 2009).
Neutralization of viral entry by binding to the MPER and inhibiting the conformational changes of gp41 required for fusion of the viral and host cell membranes (Sun et al., 2008).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human immunodeficiency virus type 1 glycoprotein 41 membrane-proximal external region (HIV-1 gp41 MPER).